Clinical trial NCT02401555 - References

HIV — Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay

Citation(s)

•   Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L
  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868-71.
•   Bond WW, Favero MS, Petersen NJ, Ebert JW
  Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals. J Clin Microbiol. 1983 Sep;18(3):535-8.
•   Brun-Vezinet F, Rey MA, Katlama C, Girard PM, Roulot D, Yeni P, Lenoble L, Clavel F, Alizon M, Gadelle S, et al
  Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet. 1987 Jan 17;1(8525):128-32.
•   Centers for Disease Control (CDC)
  AIDS due to HIV-2 infection--New Jersey. MMWR Morb Mortal Wkly Rep. 1988 Jan 29;37(3):33-5.
•   Charneau P, Borman AM, Quillent C, Guétard D, Chamaret S, Cohen J, Rémy G, Montagnier L, Clavel F
  Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology. 1994 Nov 15;205(1):247-53.
•   Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, et al
  Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986 Jul 18;233(4761):343-6.
•   Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L
  Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987 May 7;316(19):1180-5.
•   Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P, et al
  What to call the AIDS virus? Nature. 1986 May 1-7;321(6065):10.
•   Delmonico FL, Snydman DR
  Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation. 1998 Mar 15;65(5):603-10. Review.
•   Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al
  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500-3.
•   Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM, et al
  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994 Nov;68(11):7433-47.
•   George JR, Rayfield MA, Phillips S, Heyward WL, Krebs JW, Odehouri K, Soudre R, De Cock KM, Schochetman G
  Efficacies of US Food and Drug Administration-licensed HIV-1-screening enzyme immunoassays for detecting antibodies to HIV-2. AIDS. 1990 Apr;4(4):321-6.
•   Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M
  Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16-22;326(6114):662-9.
•   Janssens W, Buvé A, Nkengasong JN
  The puzzle of HIV-1 subtypes in Africa. AIDS. 1997 May;11(6):705-12. Review.
•   Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Couroucé AM, Brun-Vézinet F, Simon F
  HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet. 1994 Jun 4;343(8910):1393-4.
•   Meloni ST, Kim B, Sankalé JL, Hamel DJ, Tovanabutra S, Mboup S, McCutchan FE, Kanki PJ
  Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol. 2004 Nov;78(22):12438-45.
•   O'Brien TR, George JR, Holmberg SD
  Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA. 1992 May 27;267(20):2775-9.
•   Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U
  S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005 Sep 30;54(RR-9):1-17.
•   Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F
  A new human immunodeficiency virus derived from gorillas. Nat Med. 2009 Aug;15(8):871-2. doi: 10.1038/nm.2016. Epub 2009 Aug 2.
•   Quinn TC, Zacarias FR, St John RK
  AIDS in the Americas: an emerging public health crises. N Engl J Med. 1989 Apr 13;320(15):1005-7.
•   Resnick L, Veren K, Salahuddin SZ, Tondreau S, Markham PD
  Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA. 1986 Apr 11;255(14):1887-91.
•   Schable C, Zekeng L, Pau CP, Hu D, Kaptue L, Gurtler L, Dondero T, Tsague JM, Schochetman G, Jaffe H, et al
  Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet. 1994 Nov 12;344(8933):1333-4.
•   Sehulster LM, Hollinger FB, Dreesman GR, Melnick JL
  Immunological and biophysical alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. Appl Environ Microbiol. 1981 Nov;42(5):762-7.
•   Simon F, Mauclère P, Roques P, Loussert-Ajaka I, Müller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barré-Sinoussi F, Brun-Vézinet F
  Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med. 1998 Sep;4(9):1032-7.
•   Sullivan MT, Guido EA, Metler RP, Schable CA, Williams AE, Stramer SL
  Identification and characterization of an HIV-2 antibody-positive blood donor in the United States. Transfusion. 1998 Feb;38(2):189-93.

Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay

Details for clinical trial NCT02401555